“Amlitelimab Reduces Th2-, Th1-, and Th17 22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s603. Accessed May 2, 2026. https://skin.dermsquared.com/skin/article/view/3880.